Thursday, July 9, 2026
News

Morepen Starts Commercial Supplies Under its Rs. 825 Crore CDMO Mandate; First Rs. 50 Crore Dispatch Already Completed in Q1FY2026-27

SocialTwist Tell-a-Friend    Print this Page   COMMENT

| July 1, 2026 10:55:58 AM IST
NewsVoir

Gurugram (Haryana) [India], July 1: Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) today issued an update on its recently announced Rs. 825 crore CDMO mandate. The first commercial dispatch, valued at approximately Rs. 50 crore, has already been completed by the company under the program during Q1FY2026-27. This marks the successful transition of the mandate from validation and qualification stage to commercial execution stage.

Commenting on the development, Mr. Sanjay Suri, Managing Director, Morepen Laboratories Limited, said, "This is an important milestone in Morepen's transition toward long-duration global manufacturing partnerships. Our teams have worked closely with the customer through validation, manufacturing readiness and supply-chain planning. Having started execution of commercial supplies, we are focused on scaling up, expanding capacity and building a stronger CDMO platform across additional customer and product opportunities."

Having dispatched the first batch under the CDMO mandate, Morepen expects to scale the program further in the coming quarter, with additional supplies of approximately Rs. 225 crore expected during Q2FY2026-27, subject to customer schedules and regulatory/commercial requirements.

The Company continues to strengthen its manufacturing infrastructure to support larger CDMO opportunities. Total reactor capacity is expected to reach approximately 600 KL by the end of Q2, followed by further expansion toward 800 KL and 1,000 KL in subsequent phases.

The commencement of commercial supplies under this mandate reinforces Morepen's strategy to build a scalable CDMO platform, deepen customer partnerships and participate in long-duration global manufacturing opportunities.

About Morepen Laboratories LimitedMorepen Laboratories Limited is a pharmaceutical and healthcare company with a presence across APIs, finished formulations, diagnostics and consumer healthcare. The Company continues to strengthen its manufacturing, research and regulatory capabilities to support growth across domestic and international markets.

Safe Harbour StatementCertain statements in this release concerning future prospects, business plans, expectations and performance may be forward-looking statements. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. The Company does not undertake to update any forward-looking statements except as required by applicable law.

(ADVERTORIAL DISCLAIMER: The above press release has been provided by NewsVoir. ANI will not be responsible in any way for the content of the same.)

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE BUSINESS NEWS
'Understands business, thinks long-term'...
Sensex jumps over 300 points, Nifty near...
Supermicro Simplifies Edge AI Deployment...
Five Trends That Will Shape the Future o...
Experience Seamless Airport Transfers an...
Finance Ministry exempts customs duty on...
More...
 
INDIA WORLD ASIA
'Committed Mahapaap': Akhilesh Yadav tra...
Transparent, technology-based tax system...
Army conducts recruitment outreach progr...
Union Minister Ravneet Singh reviews Jal...
Odisha: Puri deploys 360-degree water to...
One dead, several feared trapped after u...
More...    
 
 Top Stories
Allianz Partners Appoints Carsten S... 
Iran strikes US bases in Kuwait and... 
"Complementaries in economic streng... 
Global Market Experts Share Key Inv... 
Odisha: Puri deploys 360-degree wat... 
"Understands business, thinks long-... 
SAI and Safdarjung Sports Injury Ce... 
PM Modi, Albanese to unveil economi...